KRAS and cancer: By fusing a targeting module and an endosomal escape peptide onto the delivery platform, SmiRNP successfully delivered siRNA to silence the KRAS oncogene in a colorectal carcinoma cell line, leading to cancer cell growth suppression in vitro and in vivo.